421 related articles for article (PubMed ID: 12005083)
1. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.
Chuang YY; Hung IJ; Yang CP; Jaing TH; Lin TY; Huang YC
Pediatr Infect Dis J; 2002 Mar; 21(3):203-9. PubMed ID: 12005083
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.
Mustafa MM; Carlson L; Tkaczewski I; McCracken GH; Buchanan GR
Pediatr Infect Dis J; 2001 Mar; 20(3):362-9. PubMed ID: 11303851
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.
Kebudi R; Görgün O; Ayan I; Gürler N; Akici F; Töreci K
Med Pediatr Oncol; 2001 Apr; 36(4):434-41. PubMed ID: 11260566
[TBL] [Abstract][Full Text] [Related]
4. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH
Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925
[TBL] [Abstract][Full Text] [Related]
7. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer.
Chandrasekar PH; Arnow PM
Ann Pharmacother; 2000 Sep; 34(9):989-95. PubMed ID: 10981242
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
9. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
Jimeno A; Arcediano A; Bazares S; Amador ML; González-Cortijo L; Ciruelos E; Robles L; Castellano D; Paz-Ares L; Lumbreras C; Hornedo J; Cortés-Funes H
Clin Transl Oncol; 2006 Dec; 8(12):889-95. PubMed ID: 17169762
[TBL] [Abstract][Full Text] [Related]
13. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime.
Lindblad R; Rödjer S; Adriansson M; Andreasson B; Bäckström B; Johansson P; Karlsson K; Rhedin C; Turesson I
Scand J Infect Dis; 1998; 30(3):237-43. PubMed ID: 9790130
[TBL] [Abstract][Full Text] [Related]
14. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.
Corapçioglu F; Sarper N
Pediatr Hematol Oncol; 2005; 22(1):59-70. PubMed ID: 15770833
[TBL] [Abstract][Full Text] [Related]
15. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.
Aparicio J; Oltra A; Llorca C; Montalar J; Herranz C; Gómez-Codina J; Pastor M; Munárriz B
Eur J Cancer; 1996 Sep; 32A(10):1739-43. PubMed ID: 8983283
[TBL] [Abstract][Full Text] [Related]
16. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.
Fleischhack G; Hartmann C; Simon A; Wulff B; Havers W; Marklein G; Hasan C; Bode U
J Antimicrob Chemother; 2001 Jun; 47(6):841-53. PubMed ID: 11389117
[TBL] [Abstract][Full Text] [Related]
17. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients.
Vandercam B; Gérain J; Humblet Y; Ferrant A; Wauters G; Moreau M; Longueville J; Symann M; Straetmans N
Ann Hematol; 2000 Mar; 79(3):152-7. PubMed ID: 10803938
[TBL] [Abstract][Full Text] [Related]
18. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
[TBL] [Abstract][Full Text] [Related]
19. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
